Sign in →

Test Code LAB3501 Inhibin A and B, Tumor Marker, Serum

Additional Codes

SQ: INHABM

MAYO: INHAB

Reporting Name

Inhibin A and B, Tumor Marker, S

Useful For

Aiding in the diagnosis of granulosa cell tumors and mucinous epithelial ovarian tumors

 

Monitoring of patients with granulosa cell tumors and epithelial mucinous-type tumors of the ovary known to secrete inhibin A or overexpress inhibin B

Profile Information

Test ID Reporting Name Available Separately Always Performed
INHA Inhibin A, Tumor Marker, S Yes Yes
INHB Inhibin B, S Yes Yes

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1.1 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.9 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  90 days
  Ambient  7 days

Reference Values

INHIBIN A, TUMOR MARKER

Males: <5.0 pg/mL

 

Females

<11 years: <5.0 pg/mL

11-17 years: <98 pg/mL

Premenopausal: <98 pg/mL

Postmenopausal: <5.0 pg/mL

 

INHIBIN B

Males

<15 days: 68-373 pg/mL

15-180 days: 42-516 pg/mL

6 months-7 years: 24-300 pg/mL

8-30 years: 47-383 pg/mL

31-72 years: <358 pg/mL

>72 years: Not established

 

Females

≤12 years: <183 pg/mL

13-41 years regular Cycle (Follicular Phase): <224 pg/mL

42-51 years regular Cycle (Follicular Phase): <108 pg/mL

13-51 years regular Cycle (Luteal Phase): <80 pg/mL

>51 years (Postmenopausal): <12 pg/mL

Day(s) Performed

Monday, Wednesday, Friday

CPT Code Information

83520-Inhibin B

86336-Inhibin A

LOINC Code Information

Test ID Test Order Name Order LOINC Value
INHAB Inhibin A and B, Tumor Marker, S 87426-3

 

Result ID Test Result Name Result LOINC Value
INHA Inhibin A, Tumor Marker, S 23883-2
88722 Inhibin B, S 56940-0

Method Description

The assay is performed using a Beckman Coulter Unicel DXI 800. The Access Inhibin A assay is a sequential 2-step immunoenzymatic ("sandwich'') assay. Sample is added to a reaction vessel and incubated with paramagnetic particles coupled with anti-inhibin A monoclonal antibody. Excess sample and reagents are removed, and anti-inhibin A monoclonal antibody-alkaline phosphatase conjugate is then added to a reaction mixture. After incubation, unbound materials are washed away. Antibody-analyte complex is detected by addition of the chemiluminescent substrate. The light production is directly proportional to the concentration of inhibin A in the sample.(Package insert: Access Inhibin A. Beckman Coulter Inc; 10/2023)

 

The ultra-sensitive inhibin B enzyme-linked immunosorbent assay is a quantitative three-step sandwich type immunoassay. Sample is incubated in wells that have been coated with inhibin B antibody. After incubation and washing, the wells are incubated with biotinylated inhibin B antibody. After a second incubation and washing step, the wells are incubated with streptavidin horseradish peroxidase conjugate. After the third incubation and washing step, the wells are incubated with substrate solution. After incubation, an acidic stopping solution is added. Antibody-analyte complex is detected by dual wavelength absorbance measurement at 450 nm as the primary test filter and 620 nm as the reference filter. The absorbance measured is directly proportional to the concentration of inhibin B in the samples and calibrators.(Unpublished Mayo method)

Report Available

2 to 4 days

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus OK

Method Name

INHA: Immunoenzymatic Assay

INHB: Enzyme-Linked Immunosorbent Assay (ELISA)

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

Secondary ID

86336